Nicardipine Hydrochloride in 0.9% Sodium Chloride Injection is indicated for the short-term treatment of hypertension when oral therapy is not feasible or desirable
The acquisition centers on ImCheck’s lead Phase I/II program, ICT01, a first-in-class monoclonal antibody targeting BTN3A
Acquisition aims to strengthen Merck's downstream process offering of advanced filtration and chromatography solutions
These findings follow positive Phase 3 results presented earlier this year
Phase 3 program for NDV-01 in non-muscle invasive bladder cancer expected to begin in the first half of 2026
AstraZeneca to invest $50bn in manufacturing and R&D to support domestic sourcing
Marks first international filing for Evofem’s single-dose oral treatment
Panacea Biotec receives Rs. 315 crore LoA from UNICEF
Proposed acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolio
Miels will formally assume the role on January 1, 2026
Subscribe To Our Newsletter & Stay Updated
